Literature DB >> 25047667

Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin.

M Zatz1, R C M Pavanello2, M Lazar2, G L Yamamoto2, N C V Lourenço2, A Cerqueira2, L Nogueira2, M Vainzof2.   

Abstract

Duchenne muscular dystrophy (DMD), a severe and lethal condition, is caused by the absence of muscle dystrophin. Therapeutic trials aiming at the amelioration of muscle function have been targeting the production of muscle dystrophin in affected Duchenne patients. However, how much dystrophin is required to rescue the DMD phenotype remains an open question. We have previously identified two exceptional golden retriever muscular dystrophy (GRMD) dogs with a milder course despite the total absence of muscle dystrophin. Here we report two unusual patients carrying nonsense mutations in the DMD gene and dystrophin deficiency but with an unexpectedly mild phenotype. Three reported polymorphisms, respectively in genes LTBP4, SPP1 and ACTN3 were excluded as possible DMD genetic modifiers in our patients. Finding the mechanisms that protect some rare patients and dogs from the deleterious effect of absent muscle dystrophin is of utmost importance and may lead to new avenues for treatment. Importantly, these observations indicate that it is possible to have a functional large muscle even without dystrophin.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Duchenne dystrophy; Milder progression; No dystrophin; Nonsense mutation

Mesh:

Substances:

Year:  2014        PMID: 25047667     DOI: 10.1016/j.nmd.2014.06.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

1.  Genomic removal of a therapeutic mini-dystrophin gene from adult mice elicits a Duchenne muscular dystrophy-like phenotype.

Authors:  Nalinda B Wasala; Yi Lai; Jin-Hong Shin; Junling Zhao; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2016-04-22       Impact factor: 6.150

Review 2.  Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.

Authors:  Rylie M Hightower; Matthew S Alexander
Journal:  Muscle Nerve       Date:  2017-09-22       Impact factor: 3.217

Review 3.  Outside in: The matrix as a modifier of muscular dystrophy.

Authors:  Mattia Quattrocelli; Melissa J Spencer; Elizabeth M McNally
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-12-21       Impact factor: 4.739

4.  Transplantation of Human Adipose Mesenchymal Stem Cells in Non-Immunosuppressed GRMD Dogs is a Safe Procedure.

Authors:  M V Pelatti; J P A Gomes; N M S Vieira; E Cangussu; V Landini; T Andrade; M Sartori; L Petrus; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2016-08       Impact factor: 5.739

5.  Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype.

Authors:  Natassia M Vieira; Ingegerd Elvers; Matthew S Alexander; Yuri B Moreira; Alal Eran; Juliana P Gomes; Jamie L Marshall; Elinor K Karlsson; Sergio Verjovski-Almeida; Kerstin Lindblad-Toh; Louis M Kunkel; Mayana Zatz
Journal:  Cell       Date:  2015-11-12       Impact factor: 41.582

6.  Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.

Authors:  Luca Bello; Akanchha Kesari; Heather Gordish-Dressman; Avital Cnaan; Lauren P Morgenroth; Jaya Punetha; Tina Duong; Erik K Henricson; Elena Pegoraro; Craig M McDonald; Eric P Hoffman
Journal:  Ann Neurol       Date:  2015-03-13       Impact factor: 10.422

Review 7.  Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.

Authors:  Joe W McGreevy; Chady H Hakim; Mark A McIntosh; Dongsheng Duan
Journal:  Dis Model Mech       Date:  2015-03       Impact factor: 5.758

8.  Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy.

Authors:  Nicolas A Dumont; Michael A Rudnicki
Journal:  NPJ Regen Med       Date:  2016-06-09

9.  Serum Creatinine Distinguishes Duchenne Muscular Dystrophy from Becker Muscular Dystrophy in Patients Aged ≤3 Years: A Retrospective Study.

Authors:  Liang Wang; Menglong Chen; Ruojie He; Yiming Sun; Juan Yang; Lulu Xiao; Jiqing Cao; Huili Zhang; Cheng Zhang
Journal:  Front Neurol       Date:  2017-05-08       Impact factor: 4.003

10.  Neuromuscular disorders: genes, genetic counseling and therapeutic trials.

Authors:  Mayana Zatz; Maria Rita Passos-Bueno; Mariz Vainzof
Journal:  Genet Mol Biol       Date:  2016 Jul-Sep       Impact factor: 1.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.